Desmopressin response in hemophilia A patients with FVIII:C &lt; 0.10 IU mL−1

Stoof, Sara C. M.; Sanders, Yvonne V.; Cnossen, Marjon H.; Maat, Moniek P.M. de; Leebeek, Frank W.G.; Kruip, Marieke J.H.A.

doi:10.1111/jth.12439

Cited by 5 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data are likely an underrepresentation of the general use of desmopressin: besides (mild) bleeding, patients could be applying desmopressin prophylactically, ie, before participation in sports, as was reported to be a facilitator. Despite a seemingly lower number of persons with moderate hemophilia A who reported using desmopressin in comparison with persons with mild hemophilia A in this study, previous research has shown the merits of desmopressin in persons with moderate hemophilia A [ 19 , 20 ].…”

Section: Discussioncontrasting

confidence: 62%

Desmopressin in nonsevere hemophilia A: patient perspectives on use and efficacy

Romano,

van Vulpen,

den Exter

et al. 2023

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 62%

Desmopressin in nonsevere hemophilia A: patient perspectives on use and efficacy

Romano,

van Vulpen,

den Exter

et al. 2023

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

“…We found 95% of patients to achieve FVIII:C≥0.30 IU/mL after desmopressin, including 10/13 moderate haemophilia A patients. It was previously shown that moderate haemophilia A patients can achieve these FVIII:C increases after desmopressin . Nonetheless, the response is often short lived as was the case in our study where only 1/13 moderate haemophilia A patients had FVIII:C≥0.30 IU/mL at T6.…”

Section: Discussionsupporting

confidence: 44%

Desmopressin in haemophilia: The need for a standardised clinical response and individualised test regimen

Stoof¹,

Schütte²,

Leebeek³

et al. 2017

Haemophilia

Self Cite

View full text Add to dashboard Cite

We suggest standardised desmopressin response based on clinically relevant FVIII:C levels, e.g. 0.30 and 0.50 IU/mL. In addition, patients with <0.30 IU/mL FVIII:C after 1 hour (non-responder) or ≥0.80 IU/mL (sustained responder) do not require subsequent blood sampling. However, patients with ≥0.30-0.79 IU/mL FVIII:C after 1 hour should undergo blood sampling after 6 hours to additionally determine response sustainability.

show abstract

“…570 Another analysis of 48 patients with non-severe haemophilia A evidenced a complete or partial response to DDAVP (factor VIII:C > 0.3 IU ml À1 ) in 77% of cases, sustained at 3 h post-administration in 50% of cases. 687 DDAVP was also haemostatically effective in 96% of bleeding events in haemophilia A patients tested as responders to DDAVP. 684 In a review of 114 adenotonsillectomy patients with mild bleeding disorders, including haemophilia, DDAVP was successfully used.…”

Section: Haemophilia a And B Recommendationsmentioning

confidence: 90%

Management of severe perioperative bleeding

Kozek‐Langenecker

Ahmed

Afshari

et al. 2017

European Journal of Anaesthesiology

693

316

View full text Add to dashboard Cite

: The management of perioperative bleeding involves multiple assessments and strategies to ensure appropriate patient care. Initially, it is important to identify those patients with an increased risk of perioperative bleeding. Next, strategies should be employed to correct preoperative anaemia and to stabilise macrocirculation and microcirculation to optimise the patient's tolerance to bleeding. Finally, targeted interventions should be used to reduce intraoperative and postoperative bleeding, and so prevent subsequent morbidity and mortality. The objective of these updated guidelines is to provide healthcare professionals with an overview of the most recent evidence to help ensure improved clinical management of patients. For this update, electronic databases were searched without language restrictions from 2011 or 2012 (depending on the search) until 2015. These searches produced 18 334 articles. All articles were assessed and the existing 2013 guidelines were revised to take account of new evidence. This update includes revisions to existing recommendations with respect to the wording, or changes in the grade of recommendation, and also the addition of new recommendations. The final draft guideline was posted on the European Society of Anaesthesiology website for four weeks for review. All comments were collated and the guidelines were amended as appropriate. This publication reflects the output of this work.

show abstract

Desmopressin response in hemophilia A patients with FVIII:C < 0.10 IU mL−1

Cited by 5 publications

References 9 publications

Desmopressin in nonsevere hemophilia A: patient perspectives on use and efficacy

Desmopressin in nonsevere hemophilia A: patient perspectives on use and efficacy

Desmopressin in haemophilia: The need for a standardised clinical response and individualised test regimen

Management of severe perioperative bleeding

Contact Info

Product

Resources

About